Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	ŽÁČKOVÁ Daniela KLAMOVÁ Hana MUŽÍK Jan CMUNT Edmund RÁČIL Zdeněk MACHOVÁ POLÁKOVÁ Kateřina DVOŘÁKOVÁ Dana JURČEK Tomáš RÁZGA Filip CETKOVSKÝ Petr DUŠEK Ladislav MAYER Jiří
Year of publication	2013
Type	Article in Periodical
Magazine / Source	Leukemia & Lymphoma
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://informahealthcare.com/doi/abs/10.3109/10428194.2013.772173
Doi	http://dx.doi.org/10.3109/10428194.2013.772173
Field	Oncology and hematology
Keywords	chronic myeloid leukemia; formal clinical trials; dasatinib; imatinib
Attached files	ZVV_1139161_Efficacy_and_tolerance.pdf
Description	Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.